Cargando…

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro

Emicizumab is a humanized bispecific antibody that binds simultaneously to factor (F) IXa and FX replacing the cofactor function of FVIIIa. Because emicizumab recognizes FIX/FIXa and FX/FXa, a question may arise whether emicizumab competes with antithrombin (AT) and/or tissue factor pathway inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noguchi-Sasaki, Mariko, Soeda, Tetsuhiro, Ueyama, Atsunori, Muto, Atsushi, Hirata, Michinori, Kitamura, Hidetomo, Fujimoto-Ouchi, Kaori, Kawabe, Yoshiki, Nogami, Keiji, Shima, Midori, Kitazawa, Takehisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524866/ https://www.ncbi.nlm.nih.gov/pubmed/31249933 http://dx.doi.org/10.1055/s-0038-1636538

Ejemplares similares

Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
por: Kitazawa, Takehisa, et al.
Publicado: (2017)

Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity
por: Sampei, Zenjiro, et al.
Publicado: (2014)

The Interaction of Factor Xa and IXa with Non-Activated Antithrombin in Michaelis Complex: Insights from Enhanced-Sampling Molecular Dynamics Simulations
por: Balogh, Gábor, et al.
Publicado: (2023)

A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa
por: Kundu, Sibsankar, et al.
Publicado: (2021)

Molecular Dynamics Simulation Study of the Selective Inhibition of Coagulation Factor IXa over Factor Xa
por: Yoon, Hyun Jung, et al.
Publicado: (2023)

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan
por: Matsumoto, Naoki, et al.
Publicado: (2023)

Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab
por: Mak, Stefanie, et al.
Publicado: (2022)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

Elucidating the specificity of non-heparin-based conformational activators of antithrombin for factor Xa inhibition
por: Rashid, Qudsia, et al.
Publicado: (2014)

Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency
por: Minami, Kentaro, et al.
Publicado: (2018)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
por: Yada, Koji, et al.
Publicado: (2019)

Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential
por: Nakajima, Yuto, et al.
Publicado: (2022)

Comparison of antithrombin‐dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots
por: Salta, Stella, et al.
Publicado: (2018)

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
por: Sampei, Zenjiro, et al.
Publicado: (2013)

Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A
por: Kaneda, Makoto, et al.
Publicado: (2021)

Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
por: Glonnegger, Hannah, et al.
Publicado: (2022)

Regulation of collective cell migration by RhoGAP myosin IXA
por: Omelchenko, Tatiana
Publicado: (2012)

Emicizumab-induced photosensitivity
por: Asensi Cantó, Pedro, et al.
Publicado: (2022)

Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays
por: Adamkewicz, Joanne I., et al.
Publicado: (2019)

TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity
por: Stavik, Benedicte, et al.
Publicado: (2013)

Toward non-factor therapy in hemophilia: an antithrombin insensitive Gla-domainless factor Xa as tissue factor pathway inhibitor bait
por: Dagher, Marie-Claire, et al.
Publicado: (2023)

Emicizumab state‐of‐the‐art update
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target
por: Ankrom, Wendy, et al.
Publicado: (2016)

Myosin IXa Binds AMPAR and Regulates Synaptic Structure, LTP, and Cognitive Function
por: Folci, Alessandra, et al.
Publicado: (2016)

Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)

The dosing conundrum of emicizumab: To waste product or not?
por: Young, Guy
Publicado: (2023)

A new variant in PHKA2 is associated with glycogen storage disease type IXa
por: Rodríguez-Jiménez, Carmen, et al.
Publicado: (2017)

Expression analysis of tissue factor pathway inhibitors TFPI-1 and TFPI-2 in Paralichthys olivaceus and antibacterial and anticancer activity of derived peptides
por: Wang, Guanghua, et al.
Publicado: (2021)

Peri‐operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis
por: Yagyuu, Takahiro, et al.
Publicado: (2022)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021)

ZNF354C Mediated by DNMT1 Ameliorates Lung Ischemia-Reperfusion Oxidative Stress Injury by Reducing TFPI Promoter Methylation to Upregulate TFPI
por: Shi, Qi, et al.
Publicado: (2022)

Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance
por: Ueyama, Atsunori, et al.
Publicado: (2016)

Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO
por: Reed, Christopher R., et al.
Publicado: (2021)

The role of TFPI2 hypermethylation in the detection of gastric and colorectal cancer
por: Hu, Haochang, et al.
Publicado: (2017)

TFPI-2 Protects Against Gram-Negative Bacterial Infection
por: Ali, Mohamad N., et al.
Publicado: (2018)

Association study to evaluate TFPI gene in CAD in Han Chinese
por: Zhao, Ying, et al.
Publicado: (2017)

Two ways of epigenetic silencing of TFPI2 in cervical cancer
por: Fullár, Alexandra, et al.
Publicado: (2020)

TFPI2 Promotes Perivascular Migration in an Angiotropism Model of Melanoma
por: Mo, Jing, et al.
Publicado: (2021)

Novel myostatin-specific antibody enhances muscle strength in muscle disease models
por: Muramatsu, Hiroyasu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4k6jbpo8c6p2i6bml0t0afdcld